FDA recall, , Moderate risk
Nomida Semaglutide and Tirzepatide Injections
Semaglutide and tirzepatide injections lack assurance of sterility.
Summary by Recall Canary from the FDA notice
What happened
New Life Pharma LLC, of Northvale, New Jersey, recalled Semaglutide Inj and Tirzepatide Inj sterile multi-dose vials because of a lack of assurance of sterility, the FDA announced. The products, as printed with Nomida, were added to the FDA's Enforcement Report on March 5, 2026, and the recall began February 26, 2026. The recall involves products distributed in Ohio.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Match your product and all the details in one listed combination.
An NDC (National Drug Code) is usually printed on the drug's label.
Semaglutide Inj
- Strength
- 2 mg
- NDC
- 84223-001-06
- Lot code
- 240903
- NDC
- 84223-001-07
- Lot code
- 241113
- 250103
Tirzepatide Inj
- Lot code
- 240709
- Strength
- 10 mg
- NDC
- 84223-002-03
- Strength
- 15 mg
- NDC
- 84223-002-04
Recall details
- Company began the recall
- Sold in
- Company
- New Life Pharma LLCNorthvale, New Jersey
- Hazard
- Sterility problem
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 98496
- Recall numbers
- D-0392-2026 to D-0395-2026
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report
In FDA's weekly enforcement report
Classified by FDA
Listed on Recall Canary
Summary updated
